Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of XAF5 Gel for Reduction of Submental Fat.

X
Trial Profile

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of XAF5 Gel for Reduction of Submental Fat.

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XAF 5 (Primary)
  • Indications Adipose tissue disorders
  • Focus Therapeutic Use
  • Sponsors Topokine Therapeutics
  • Most Recent Events

    • 26 Feb 2016 According to ClinicalTrials.gov record, the primary endpoint has been amended and hence the trial focus has changed from TU to AR
    • 26 Feb 2016 Status changed from recruiting to suspended, according to ClinicalTrials.gov record.
    • 19 Nov 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2016, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top